Structure-based design of type II inhibitors applied to maternal embryonic leucine zipper kinase

ACS Medicinal Chemistry Letters

Volumn 6, Issue 1, 2015, Pages 31-36

  Johnson, Christopher N ^a   Adelinet, Christophe ^b   Berdini, Valerio ^a   Beke, Lijs ^b   Bonnet, Pascal ^b,c   Brehmer, Dirk ^b   Calo, Frederick ^a   Coyle, Joseph E ^a   Day, Phillip J ^a   Frederickson, Martyn ^a   Freyne, Eddy J E ^b   Gilissen, Ron A H J ^b   Hamlett, Christopher C F ^a   Howard, Steven ^a   Meerpoel, Lieven ^b   Mevellec, Laurence ^b   McMenamin, Rachel ^a   Pasquier, Elisabeth ^b   Patel, Sahil ^a   Rees, David C ^a   Linders, Joannes T M ^b   more..

^a ASTEX PHARMACEUTICALS   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Université d'Orléans   (France)

Author keywords

fragment based drug design; Maternal embryonic leucine zipper kinase; structure based optimization

Indexed keywords

CELL PENETRATING PEPTIDE; LEUCINE ZIPPER PROTEIN; PHOSPHOTRANSFERASE INHIBITOR;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; MOLECULE; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRUCTURE BASED OPTIMIZATION; X RAY CRYSTALLOGRAPHY;

EID: 84920713510     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5001273     Document Type: Article

References (18)

1. Gray, D.; Jubb, A. M.; Hogue, D.; Dowd, P.; Kljavin, N.; Yi, S.; Bai, W.; Frantz, G.; Zhang, Z.; Koeppen, H.; de Sauvage, F. J.; Davis, D. P. Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers Cancer Res. 2005, 65, 9751-9761
2. Nakano, I.; Masterman-Smith, M.; Saigusa, K.; Paucar, A. A.; Horvath, S.; Shoemaker, L.; Watanabe, M.; Negro, A.; Bajpai, R.; Howes, A.; Lelievre, V.; Waschek, J. A.; Lazareff, J. A.; Freije, W. A.; Liau, L. M.; Gilbertson, R. J.; Cloughesy, T. F.; Geschwind, D. H.; Nelson, S. F.; Mischel, P. S.; Terskikh, A. V.; Kornblum, H. I. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells J. Neurosci. Res. 2008, 86, 48-60
3. Pickard, M. R.; Green, A. R.; Ellis, I. O.; Caldas, C.; Hedge, V. L.; Mourtada-Maarabouni, M.; Williams, G. T. Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer Breast Cancer Res. 2009, 11, R60
4. Lin, M.-L.; Park, J.-H.; Toshihiko Nishidate, T.; Nakamura, Y.; Katagiri, T. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family Breast Cancer Res. 2009, 11, R17
5. Kuner, R.; Fälth, M.; Pressinotti, N. C.; Brase, J. C.; Puig, S. B.; Metzger, J.; Gade, S.; Schäfer, G.; Bartsch, G.; Steiner, E.; Klocker, H.; Sültmann, H. The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer J. Mol. Med. 2013, 91, 237-248
6. Ryu, B.; Kim, D. S.; DeLuca, A. M.; Alani, R. M. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression PLoS One 2007, 2, e594
7. Ku, J.-L.; Shin, Y.-K.; Kim, D.-W.; Kim, K.-H.; Choi, J.-S.; Hong, S.-H.; Jeon, Y.-K.; Kim, S.-H.; Kim, H.-S.; Park, J.-H.; Kim, I.-J.; Park, J.-G. Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers Carcinogenesis 2010, 31, 1003-1009
8. Chung, S.; Suzuki, H.; Miyamoto, T.; Takamatsu, N.; Tatsuguchi, A.; Ueda, K.; Kijima, K.; Nakamura, Y.; Matsuo, Y. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer Oncotarget 2012, 3, 1629-1640
9. Jhoti, H.; Williams, G.; Rees, D. C.; Murray, C. W. The rule of three' for fragment-based drug discovery: where are we now? Nat. Rev. Drug Discovery 2013, 12, 644-645
10. Johnson, C. N.; Berdini, V.; Beke, L.; Bonnet, P.; Brehmer, D.; Coyle, J. E.; Day, P. J.; Frederickson, M.; Freyne, E. J. E.; Gilissen, R. A. H. J.; Hamlett, C. C. F.; Howard, S.; Meerpoel, L.; McMenamin, R.; Patel, S.; Rees, D. C.; Sharff, A.; Sommen, F.; Wu, T.; Linders, J. T. M. Fragment-Based Discovery of Selective Type I Inhibitors of Maternal Embryonic Leucine Zipper Kinase ACS Med. Chem. Lett. 2014, 10.1021/ml5001245
11. Blanc, J.; Geney, R.; Menet, C. Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design Anti-Cancer Agents Med. Chem. 2013, 13, 731-747
12. 50)/HAC. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
13. Schroeder, G. M.; Chen, X. T.; Williams, D. K.; Nirschl, D. S.; Cai, Z. W.; Wei, D.; Tokarski, J. S.; An, Y.; Sack, J.; Chen, Z.; Huynh, T.; Vaccaro, W.; Poss, M.; Wautlet, B.; Gullo-Brown, J.; Kellar, K.; Manne, V.; Hunt, J. T.; Wong, T. W.; Lombardo, L. J.; Fargnoli, J.; Borzilleri, R. M. Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase Bioorg. Med. Chem. Lett. 2008, 18, 1945-1951
14. Murray, C. W.; Verdonk, M. L.; Rees, D. C. Experiences in fragment-based drug discovery Trends Pharmacol. Sci. 2012, 33, 224-232
15. Nilson, M. G.; Funk, R. L. Total synthesis of (±)-cortistatin J from furan J. Am. Chem. Soc. 2011, 133, 12451-12453
16. Griffith, J.; Black, J.; Faerman, C.; Swenson, L.; Wynn, M.; Lu, F.; Lippke, J.; Saxena, K. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain Mol. Cell 2004, 13, 169-178
17. Warmuth, M.; Kim, S.; Gu, X.-J.; Xia, G.; Adrián, F. Ba/F3 cells and their use in kinase drug discovery Curr. Opin. Oncol. 2007, 19, 55-60
18. O'Hare, T.; Shakespeare, W. C.; Zhu, X.; Eide, C. A.; Rivera, V. M.; Wang, F.; Adrian, L. T.; Zhou, T.; Huang, W. S.; Xu, Q.; Metcalf, C. A.; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y.; Keats, J. A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W.; Druker, B. J.; Clackson, T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 2009, 16, 401-412